The MiniMed insulin pump lawsuit is a wave of product liability claims against Medtronic brought by Type 1 diabetics who say defective retainer rings in the company’s 600-series pumps caused dangerous insulin dosing errors, leading to severe hypoglycemia, hyperglycemia, diabetic coma, and in some cases death. Hundreds of cases are pending. No global settlement exists. The lead cases, consolidated in Los Angeles Superior Court, have survived Medtronic’s attempts to dismiss them and are moving toward trial.
What Went Wrong With the Pumps
The defect at the center of the litigation is a small plastic part called the retainer ring, which locks the insulin reservoir into the pump. On affected MiniMed 630G and 670G models, the original clear retainer ring was prone to cracking or breaking, especially if the pump was dropped or bumped against a hard surface. When the ring failed, the reservoir could come loose, and the pump would deliver insulin either too quickly or too slowly.
The consequences of that malfunction are serious. An overdose of insulin can send blood sugar plummeting to life-threatening lows. An underdose can push blood sugar dangerously high and trigger diabetic ketoacidosis. In one Missouri lawsuit filed in August 2023, the estate of Michael E. Domanowski alleged that a malfunctioning MiniMed pump delivered a week’s worth of insulin at once, causing a fatal overdose.1AboutLawsuits.com. Medtronic MiniMed Lawsuit: Wrongful Death From Insulin Overdose That case was dismissed in September 2024 after the parties filed a stipulation of dismissal, with a scheduled mediation cancelled after the parties notified the court of a settlement.2PACER Monitor. Frank v. Medtronic Minimed, Inc. et al
Which MiniMed Pumps Were Recalled
Medtronic began recalling the affected pumps in November 2019 after receiving more than 26,000 complaints, including 2,175 injury reports and one reported death.3AboutLawsuits.com. Medtronic MiniMed The FDA classified the action as a Class I recall, its most serious designation, in February 2020. The recall covered over 300,000 MiniMed 630G and 670G units distributed between 2016 and 2019.4AACE. Recall: Medtronic MiniMed Insulin Pumps Recalled for Incorrect Insulin Dosing
At first, Medtronic replaced only rings that showed visible damage. In October 2021, the company expanded the recall to proactively replace all 600-series pumps containing the clear retainer ring with updated models featuring a black retainer ring design.5Medtronic Newsroom. Update to Recall of MiniMed 600 Series Insulin Pumps With Clear Retainer Rings The expansion brought the total number of affected devices to roughly 500,000.3AboutLawsuits.com. Medtronic MiniMed
Other MiniMed safety actions have followed. In September 2022, the FDA identified a cybersecurity vulnerability in MiniMed 620G and 640G pumps that could allow unauthorized access to the communication protocol and unintended insulin delivery. That Class II recall covered over 316,000 units.6FDA. Class II Device Recall MiniMed 600 Series Insulin Pump Systems In October 2024, Medtronic issued an urgent correction for the 600 and 700 series, including the 630G, 670G, 770G, and 780G, after reports that physical impacts could damage electrical components, shorten battery life, and cause the pump to shut down unexpectedly during insulin delivery. The FDA classified that action as Class I. Between January 2023 and September 2024, the agency received 170 reports of severe hyperglycemia and 11 reports of diabetic ketoacidosis tied to the battery issue, with no deaths reported from that specific defect.7FDA. Insulin Pump Recall: Medtronic Notifies Users of MiniMed 600 and 700 Series Pumps of Risk of Shorter Expected Battery Life
Injuries and Deaths Linked to MiniMed Pumps
The harm attributed to Medtronic insulin pumps extends well beyond the retainer ring alone. An investigation by the International Consortium of Investigative Journalists, published in November 2018, linked Medtronic insulin pumps to approximately 150,000 injuries and 2,600 deaths over the prior decade, along with 20 recalls and about 100 lawsuits at that time.8Drug Delivery Business. Medtronic’s Insulin Pumps Highlighted in MedTech Injury Report Health Canada data covering a similar ten-year window tied insulin pumps to 103 deaths and more than 1,900 injuries in Canada alone.9CBC News. Implant Files: Insulin Pumps
A 2024 study in the Journal of Diabetes Science and Technology analyzed FDA adverse event reports filed between May 2019 and January 2021 across all major insulin pump brands. Researchers identified 745 severe adverse events, including 460 ICU admissions and 288 deaths. Diabetic ketoacidosis was the most common consequence among ICU admissions, cited in over 73% of cases. Twenty-seven ICU admissions and 20 deaths were specifically linked to a damaged or missing retainer ring.10National Library of Medicine. Severe Adverse Events Associated With Insulin Pumps
Where the Lawsuits Stand
Lawsuits over the MiniMed pumps are moving through both state and federal courts. There is no multidistrict litigation consolidating the cases at the federal level, so suits have proceeded in separate courts.
Federal Preemption Has Been a Hurdle
Medtronic has argued in federal court that because the MiniMed pumps received Premarket Approval from the FDA as high-risk Class III devices, state-law product liability claims are barred under the Medical Device Amendments to the Food, Drug, and Cosmetic Act. The Supreme Court endorsed this general framework in its 2008 decision in Riegel v. Medtronic.
Two federal judges accepted the argument in June 2023. In Warmoth v. Medtronic, Judge Scott L. Palk of the Western District of Oklahoma dismissed the case with prejudice, ruling that design defect claims sought to impose requirements different from or in addition to what the FDA had approved and that the plaintiff failed to identify a parallel federal violation. Days later, in Benn v. Medtronic, Judge Evelyn Padin of the District of New Jersey dismissed all claims on similar preemption grounds, though without prejudice. Judge Padin specifically rejected the argument that a product recall alone establishes a violation of federal specifications.11AboutLawsuits.com. Medtronic MiniMed Insulin Pump Lawsuits Preempted Neither ruling binds other courts.
The Lead California Cases Are Heading to Trial
The most significant litigation is in California state court, where Medtronic has been less successful in blocking claims. The lead cases are Davis et al. v. Medtronic MiniMed Inc. and Burgess et al. v. Medtronic MiniMed Inc., handled by Judge Elihu Berle in the Complex Division of Los Angeles Superior Court.
On March 27, 2025, Judge Berle denied Medtronic’s motion for summary judgment based on the statute of limitations. The court found the plaintiffs had established a prima facie case of fraudulent concealment, pointing to evidence that Medtronic had actual knowledge of the retainer ring defect as early as 2016 and was motivated to conceal the problem to continue selling its pump systems and avoid liability.12Yahoo Finance. Cowper Law LLP Defeats Medtronic’s Motion for Summary Judgment in MiniMed Insulin Pump Litigation Cowper Law LLP, which represents the plaintiffs, has said it represents over 1,000 Type 1 diabetics who used the recalled 600-series pumps.13Nasdaq. Cowper Law LLP Defeats Medtronic’s Motion for Summary Judgment in MiniMed Insulin Pump Litigation
Medtronic asked the California Court of Appeal to overturn Judge Berle’s decisions denying the company’s motions to apply the laws of plaintiffs’ home states instead of California law and to sever the consolidated cases into separate trials. On October 14, 2025, the appellate court denied the writ in Medtronic MiniMed, Inc. et al. v. Superior Court Los Angeles County et al. (Case No. B348034), finding Medtronic had shown no legal error or abuse of discretion by the trial judge.14Cowper Law. Cowper Law Defeats Medtronic Inc. Again: California Appellate Court Denies Medtronic’s Writ of Mandate The cases were scheduled for trial beginning July 21, 2025.12Yahoo Finance. Cowper Law LLP Defeats Medtronic’s Motion for Summary Judgment in MiniMed Insulin Pump Litigation
What the FDA Found About Medtronic’s Conduct
The FDA’s scrutiny went beyond recalls. Following an inspection of Medtronic’s Northridge, California, manufacturing facility in the summer of 2021, the FDA issued a formal warning letter on December 9, 2021, citing violations of manufacturing quality regulations and adverse event reporting requirements.15FDA. Medtronic, Inc. Warning Letter
The agency found that despite receiving over 74,000 complaints about the clear retainer ring, Medtronic did not initiate a recall until November 2019 and had underestimated the probability of patient harm in its risk assessments. The FDA also faulted the company for failing to investigate more than 800 complaints about the redesigned black retainer rings, with Medtronic improperly citing a closed corrective action from the earlier clear-ring problem as justification for not looking into the new reports. The letter identified failures in timely reporting of serious injuries, citing at least one instance in which a patient suffered dangerously low blood glucose following a pump malfunction that was not reported within the required 30-day window.15FDA. Medtronic, Inc. Warning Letter
Medtronic said it brought in external experts and completed roughly 90% of the FDA’s required corrective actions by fall 2022. The FDA lifted the warning letter on April 25, 2023, and Medtronic announced that all regulatory restrictions had been resolved.16Medtronic Newsroom. Medtronic Diabetes Resolves Warning Letter, Clearing Path for Future Innovations No consent decree or further enforcement action resulted.17Drug Delivery Business. Medtronic Diabetes Resolves FDA Warning Letter
Who Can Still Bring a Claim
The California litigation is the most active track for injury claims tied to the retainer ring defect. Lawyers involved in the lead cases have said they represent over 1,000 Type 1 diabetics who used the recalled 600-series pumps, and Judge Berle’s ruling on fraudulent concealment has kept the door open for plaintiffs whose injuries date back years. If you used a MiniMed 630G or 670G pump with a clear retainer ring and suffered a severe hypoglycemic episode, diabetic ketoacidosis, coma, or the death of a family member, a product liability attorney can evaluate whether your claim fits within an existing case or the applicable statute of limitations.
The recalls remain formally open. The 2020 retainer ring recall has not been closed, and the more recent 2024 battery-related recall for the 600 and 700 series continues to affect users of current-generation pumps.7FDA. Insulin Pump Recall: Medtronic Notifies Users of MiniMed 600 and 700 Series Pumps of Risk of Shorter Expected Battery Life Users of any affected model should confirm with Medtronic or their healthcare provider whether their device has been replaced.